Exchange: NASDAQ·Updated 07:26 PM EST
MTVA logo

MTVA MetaVia Inc.

$1.05
$0.06
(5.61%)
Today
Closed $1.01
$0.04
(3.96%)
After Hours
Mkt Cap$6.81M
Vol39,529.00

About MTVA

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, engineered with a 3:1 GLP1R:GCGR potency ratio. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated placebo-adjusted reductions of 13.5% in body weight and 68% in liver fat, along with reductions in visceral and subcutaneous adipose tissue and relatively preserved lean mass. A Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, is targeted to begin in the second half of 2027. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). It acts directly in the liver on pathways involved in steatosis, inflammation and fibrosis, while GPR119 activation in the pancreas and gut also supports glucose and metabolic regulation. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects. MetaVia is advancing vanoglipel in combination with resmetirom as a once-daily oral combination therapy for MASH, with a Phase 2a proof-of-concept study targeted to begin in the first half of 2027.
28

Bearish Sentiment

How do you feel about MTVA?

xTheEi8htx
$MTVA is it just me or does this look like it wants to rip even more? Ei8ht Watchlist After Hours — 4:00–8:00 PM ET 1. $INDI 2. $ARQ 3. $CCLD 4. $AMTX
7
Kertzi
$MTVA MASSIVE DILUTION AHEAD. BANKRUPTCY RISK CANNOT BE RULED OUT. The company has cash runway only into Q1 2027, according to its own investor presentation. Reverse split → ATM / new offering → warrants → massive dilution. Look at the shareholder value destruction since 2017... Horrible.
1
1
Invescent
SMALL-CAP STOCKS TO WATCH | NOV 4 FRESH CATALYSTS, LOW FLOAT & SHORT INTEREST $MTVA — ~4.66M float | 2.12% short Phase 1 obesity drug data presentation today. $KTTA — ~32.94M float | 0.53% short FDA IND clearance and clinical event today. $BLSM — New cancer drug clinical data announcement. $ACIU — 39.18M float Parkinson's Phase 2 update and FDA Fast Track progress. $RYTM — Expanded UK treatment guidance announced today. Watching for unusual volume, momentum and potential breakouts.
1
1
xTheEi8htx
$MTVA Still looking good here, let's see volume at open. Ei8ht Watchlist Market Open — 9:30–11:00 AM ET 1. $EDSA 2. $INLF 3. $YMAT 4. $TGE
1
xTheEi8htx
$MTVA let's see some volume and run this back to top of trend at least. Ei8ht Watchlist Market Open — 9:30–11:00 AM ET 1. $RAYA 2. $CENN 3. $COYA 4. $PLBY
1
Rayvio_News_Filter
$MTVA 🏥 MetaVia Inc. reported positive interim Phase 1 Part 3B data for DA-1726, with statistically significant 68% liver fat reduction, 13.5% placebo-adjusted weight loss, and HbA1c reduction, supporting a planned 48-week Phase 2 study in up to 150 patients with MetALD and ALD. Prioritized by relevance
1
Kertzi
$MTVA The Dong-A (Korea) risk nobody seems to be discussing. MetaVia reportedly owes Dong-A ST approximately $2.1 million, including overdue invoices and accrued clinical costs. Dong-A is not just a major shareholder — it is also a key supplier, the original developer and the licensor of both drug candidates. What happens if Dong-A decides it has had enough? It could demand payment and, if contractual conditions are met, suspend services or terminate agreements. Losing Dong-A's support could seriously disrupt the development of both assets. With cash running low, Nasdaq's minimum equity requirement already breached, and no clear financing solution in sight, this is a serious risk shareholders should not ignore. Could Dong-A be MetaVia's biggest lifeline — or ultimately the reason this company runs out of road?
Joefreeagent
$MTVA On November 17, 2026, MetaVia Inc. (the “Company”) received written notice from the Nasdaq Stock Market (“Nasdaq”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because the Company’s stockholders’ equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, has fallen below $2.5 million. The notice also indicates that the Company does not meet the alternative compliance standards. SCAM.. SCAM..SCAM!
Kertzi
$MTVA ANNUAL TRADITION, DELISTING WARNING TO KOREAN SCAM https://www.sec.gov/Archives/edgar/data/1638287/000110465926129393/mtva-20261117x8k.htm Can they actually raise enough new capital to keep this Ponzi operation alive, or will Dong-A finally pull the plug?
focafoca99
$MTVA illustrates positive preclinical data for DA-1726, a dual OXM analog beating retatrutide in weight-loss and metabolic studies.
Rayvio_News_Filter
$MTVA 🏥 MetaVia Inc. announced additional positive Phase 1 Part 3B clinical trial data for DA-1726 showing a 1.47 mg/dL placebo-adjusted reduction in uric acid (p<0.001), 13.5% placebo-adjusted weight loss, and normalization of liver fat in subjects with baseline steatosis, advancing it toward a planned Phase 2 study in MetALD and ALD in the second half of 2027. Curated for market relevance
BiotechSwings
31% Friday and $MTVA earned every bit of it DA 1726 cut liver fat 68% vs placebo at day 109, body weight down 13.5% too tiny trial, 15 treated and 4 on placebo. early days, i know still, 10 of 12 hit at least 30% liver fat reduction and all 5 with steatosis cleared under 5% full data lands Q1 2027, Phase 2 in liver disease starts second half of next year
focafoca99
$MTVA showcases positive interim Phase 1 data for DA-1726, its novel OXM analog targeting GLP-1 and glucagon receptors.

Advertisement|Remove ads.